{"denoms":[{"counts":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"462"}],"units":"Participants"}],"groups":[{"description":"Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).","id":"BG000","title":"Fulvestrant 500 mg"},{"description":"Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \\[±3\\], 28 \\[±3\\] and every 28 \\[±3\\] days thereafter).","id":"BG001","title":"Anastrozole 1 mg"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"38","spread":"9.86","upperLimit":"87","value":"63.8"},{"groupId":"BG001","lowerLimit":"36","spread":"10.38","upperLimit":"90","value":"63.3"},{"groupId":"BG002","lowerLimit":"36","spread":"10.12","upperLimit":"90","value":"63.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"462"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"70"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"174"},{"groupId":"BG002","value":"349"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The intention to treat (ITT) analysis set included all randomised patients."}